Amphista Therapeutics

A new approach to protein degradation

Amphista Therapeutics is using a novel mechanism of targeted protein degradation (TPD) to hijack the cell’s degradation machinery to modulate the abundance of proteins that are responsible for disease progression.

Powered by transformational science, they are advancing beyond traditional degrader approaches using their proprietary Eclipsys™ Drug Development Platform. Amphista’s approach to protein degradation differentiates from traditional TPD technologies by expanding the scope for therapeutic applications and reducing the risk of resistance in oncology indications.

CEO  Beverley Carr

Advent Contact  Dominic Schmidt

Advent founded and seeded Amphista in 2018.
Private Companies
24 January 2024 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders

Press Release.   Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders   First demonstration of efficacy in disease-relevant in…
Read More
26 September 2023 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb

Press Release.   PRESS RELEASE   Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb   Cambridge, UK, September 26th, 2023 – Amphista Therapeutics (“the Company”…
Read More
4 May 2023 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb

Press Release.   Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb 4 May 2023 CAMBRIDGE, UK, May 4, 2023 - Amphista Therapeutics, a leader in next…
Read More
12 September 2022 in Amphista Therapeutics, Press Release, Private Companies

Fierce Biotech Names Amphista Therapeutics as One of its “Fierce 15” Biotech Companies of 2022

Press Release.   Cambridge, UK – September, 12, 2022 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it…
Read More
4 May 2022 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics

Press Release.   Amphista and Merck will collaborate to leverage Amphista’s proprietary EclipsysTM TPD platform and generate novel protein degrading therapeutics in oncology and immunology Collaboration includes  up to €39…
Read More
4 May 2022 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics

Press Release.   Amphista and Bristol Myers Squibb to collaborate and leverage Amphista’s proprietary Eclipsys™ targeted protein degradation platform to develop novel protein degrading therapeutics Collaboration includes an upfront payment…
Read More
6 December 2021 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics Appoints Dr Martin Pass as CDO

Press Release.   Amphista Therapeutics Appoints Dr Martin Pass as CDO Cambridge, England, 6 December 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today…
Read More
1 November 2021 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics Appoints CBO, Beverley Carr

Press Release.   Amphista Therapeutics Appoints CBO, Beverley Carr Cambridge, England, 1 November 2021 - Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the…
Read More
21 September 2021 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm

Press Release.   Glasgow, UK, 21 September 2021 - Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as…
Read More
28 June 2021 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics Expands Research Team by Appointing Martin O’Rourke as Head of Drug Discovery and James Osborne as Director of Chemistry

Press Release.   Glasgow, Scotland, 28 June 2021 - Amphista Therapeutics, a Targeted Protein Degradation (TPD) biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes to remove…
Read More
17 March 2021 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets

Press Release.   Financing includes leading life-science investors Gilde Healthcare, Forbion, Novartis Venture Fund and Eli Lilly and Company   Glasgow, UK, 17 March 2021 - Amphista Therapeutics, a leader…
Read More
21 May 2020 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics appoints leading protein degradation pioneer, Ian Churcher as CSO

Press Release.   Glasgow, Scotland, 21 May 2020 - Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes to remove disease causing proteins selectively…
Read More
7 April 2020 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics raises $7.5m Series A round to advance targeted protein degradation assets in cancer

Press Release.   April 7, 2020 Amphista’s potent bifunctional small molecules augment targeted protein degradation Investors include Advent Life Sciences, the Scottish Investment Bank, the European Investment Fund and US-based…
Read More